Human Ly6/PLAUR domain-containing protein 3(LYPD3) ELISA kit

Code CSB-EL013263HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name LY6/PLAUR domain containing 3
Alternative Names 2310061G07Rik ELISA Kit; C4.4A ELISA Kit; GPI-anchored metastasis-associated protein C4.4A homolog ELISA Kit; GPI-anchored metastasis-associated protein homolog ELISA Kit; Ly6/PLAUR domain-containing protein 3 ELISA Kit; Lypd3 ELISA Kit; LYPD3_HUMAN ELISA Kit; Matrigel-induced gene C4 protein ELISA Kit; MIG-C4 ELISA Kit; SHINC3 ELISA Kit
Abbreviation LYPD3
Uniprot No. O95274
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 31.25 pg/mL-2000 pg/mL
Sensitivity 7.81 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cancer
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human LYPD3 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
SampleSerum(n=4)
1:1Average %101
Range %94-105
1:2Average %88
Range %81-93
1:4Average %94
Range %87-97
1:8Average %92
Range %84-96
Recovery
The recovery of human LYPD3 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9087-94
EDTA plasma (n=4)9285-97
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
20002.626 2.446 2.536 2.378
10002.228 2.113 2.171 2.013
5001.506 1.488 1.497 1.339
2500.803 0.785 0.794 0.636
1250.502 0.491 0.497 0.339
62.50.377 0.364 0.371 0.213
31.250.246 0.251 0.249 0.091
00.156 0.160 0.158
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression.
Gene References into Functions
  1. While in the healthy liver hepatocytes are C4.4A negative, data show that C4.4A is strongly expressed in hepatocellular carcinoma (HCC) with upregulation at the invasive front and in lung metastasis, indicating that C4.4A apparently contributes to HCC progression. PMID: 29048672
  2. Our results are consistent with previous data in mouse embryogenesis and wound healing. Based on these findings, we conclude that this human TES model provides an excellent surrogate for studies of C4.4A and Haldisin expressions in human stratified epithelia. PMID: 29075641
  3. Expression and crystallographic studies of the D1D2 domains of C4.4A have been reported. PMID: 28777093
  4. LYPD3 has a role in the maintenance of colorectal cancer stem-like cells. PMID: 28238780
  5. Highly expressed C4.4A protein in HER2-positive human breast cancers indicate a good prognosis. PMID: 23918676
  6. overexpression of C4.4A correlates with metastatic potential of gastric cancer and C4.4A could be a novel independent prognostic marker for predicting outcome. PMID: 24935570
  7. expression of the Ly6/uPAR-domain proteins C4.4A and Haldisin in non-invasive and invasive skin lesions PMID: 25414274
  8. Tenascin-C expression was significantly associated with C4.4A expression in clinical esophageal squamous carcinoma samples suggesting that there may be a functional role for the C4.4A to induceTenascin-C in vivo. PMID: 23708783
  9. findings suggest that a tight association between C4.4A and tumor budding may, in part, be due to C4.4A promoting epithelial-mesenchymal transition at the invasive front of colorectal cancer PMID: 22404718
  10. the first explanation for the C4.4A contribution to wound healing and metastasis. PMID: 22431918
  11. data indicate that expression of the C4.4A protein at the invasive front acts as a novel prognostic marker in colorectal cancer, possibly through invasion-related mechanisms PMID: 20825414
  12. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan PMID: 12592373
  13. High tumour cell C4.4A expression is associated with shorter survival for non-small cell lung cancer patients. PMID: 17706320
  14. Overexpression of C4.4A is associated with invasion and metastasis of esophageal squamous cell carcinoma PMID: 17849475
  15. we consider C4.4A as a candidate diagnostic marker in colorectal cancer, which possibly can be detected in body fluids PMID: 17912244
  16. cleavage of C4.4A by ADAM10 and ADAM17 contributes to tumor progression PMID: 18979631

Show More

Hide All

Subcellular Location Cell membrane; Lipid-anchor, GPI-anchor.
Tissue Specificity Expressed in placenta, skin and urothelium. Found in suprabasal keratinocytes of chronic wounds. Weak expression is found in esophagus and peripheral blood mononuclear cells. Found in the majority of primary and metastatic transitional cell carcinomas (TC
Database Links

HGNC: 24880

OMIM: 609484

KEGG: hsa:27076

STRING: 9606.ENSP00000244333

UniGene: Hs.631594

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1